Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
J Physiol ; 586(5): 1337-49, 2008 Mar 01.
Article in English | MEDLINE | ID: mdl-18187464

ABSTRACT

Neuronal activity is tightly coupled with brain energy metabolism. Numerous studies have suggested that lactate is equally important as an energy substrate for neurons as glucose. Lactate production is reportedly triggered by glutamate uptake, and independent of glutamate receptor activation. Here we show that climbing fibre stimulation of cerebellar Purkinje cells increased extracellular lactate by 30% within 30 s of stimulation, but not for briefer stimulation periods. To explore whether lactate production was controlled by pre- or postsynaptic events we silenced AMPA receptors with CNQX. This blocked all evoked rises in postsynaptic activity, blood flow, and glucose and oxygen consumption. CNQX also abolished rises in lactate concomitantly with marked reduction in postsynaptic currents. Rises in lactate were unaffected by inhibition of glycogen phosphorylase, suggesting that lactate production was independent of glycogen breakdown. Stimulated lactate production in cerebellum is derived directly from glucose uptake, and coupled to neuronal activity via AMPA receptor activation.


Subject(s)
Cerebellum/metabolism , Glucose/metabolism , Lactates/metabolism , Oxygen/metabolism , Receptors, AMPA/metabolism , 6-Cyano-7-nitroquinoxaline-2,3-dione/pharmacology , Animals , Cerebellum/blood supply , Excitatory Amino Acid Antagonists/pharmacology , Male , Neuroglia/metabolism , Purkinje Cells/metabolism , Rats , Rats, Wistar , Receptors, AMPA/antagonists & inhibitors , Receptors, AMPA/drug effects , Regional Blood Flow/physiology , Synapses/drug effects , Synapses/physiology
2.
Neurosci Res ; 47(4): 431-6, 2003 Dec.
Article in English | MEDLINE | ID: mdl-14630347

ABSTRACT

Although the issue of in vivo levodopa toxicity appears to be settled by now in the light of recent findings, a crucial aspect was not accounted for the experiments designed to tackle that question. Levodopa could in fact be non-toxic on surviving dopamine neurons, but that could not be the case when the drug is administered at the same time those neurons are undergoing degeneration, which is what happens in the clinical setting. Dopaminergic neurons could in that situation be more vulnerable to levodopa's potential toxic action. Our aim was to determine if oral administration of levodopa is toxic for mesencephalic dopaminergic neurons that are actively involved in a degenerative process. We induced delayed retrograde degeneration of the nigrostriatal system in rats by injecting 6-hydroxydopamine (6-OHDA) intrastriatally. Treatment was started the day after the injection. Dopaminergic markers were histologically studied at the striatal and nigral levels, to determine degree of damage of the nigrostriatal dopaminergic system in levodopa- and vehicle-treated rats. No significant differences between levodopa or vehicle-treated rats were found in: (i) striatal immunoautoradiographic labeling for tyrosine hydroxylase (TH) and the membrane dopamine transporter (DAT); (ii) cell counts of TH-immunoreactive (TH-ir) neurons remaining in the substantia nigra and ventral tegmental area (VTA); (iii) surface area of remaining TH-immunoreactive neurons in the substantia nigra. The present experiments demonstrate that levodopa does not enhance delayed retrograde degeneration of dopaminergic neurons induced by intrastriatal administration of 6-OHDA.


Subject(s)
Antiparkinson Agents/pharmacology , Levodopa/pharmacology , Nerve Degeneration/drug therapy , Neurons/drug effects , Administration, Oral , Animals , Antiparkinson Agents/administration & dosage , Disease Models, Animal , Dopamine/metabolism , Female , Immunohistochemistry , Injections, Intraventricular , Levodopa/administration & dosage , Mesencephalon/drug effects , Mesencephalon/pathology , Nerve Degeneration/chemically induced , Nerve Degeneration/pathology , Neurons/pathology , Oxidopamine/administration & dosage , Oxidopamine/toxicity , Parkinsonian Disorders/drug therapy , Rats , Rats, Wistar , Time Factors , Tyrosine 3-Monooxygenase/drug effects , Tyrosine 3-Monooxygenase/metabolism
3.
Brain Res Dev Brain Res ; 145(1): 9-17, 2003 Oct 10.
Article in English | MEDLINE | ID: mdl-14519489

ABSTRACT

In order to understand the relationship between astrocytes, microglia and injured neurons, we studied the weaver mutant mouse. One of the main characteristics of this mutant is the progressive degeneration of the dopaminergic (DA) nigrostriatal pathway that starts around postnatal day 15 (P15), in the substantia nigra pars compacta (SNpc) and progresses until adult age (P60). In the present paper, we analysed the relationship between astroglial and microglial cells within DA neurons in the nigrostriatal system of homozygous weaver mice, at different postnatal ages corresponding to specific stages of the DA neuronal loss. The activation of astrocytes was found to be an early event in weaver DA denervation, appearing massively at the onset of DA neuronal loss in the SNpc at P15. Astrocytes remained activated in the adult brain even after the slowing down of the neuronal death process. Interestingly, in the ventral tegmental area, where no DA neuronal death could be detected, a profound, permanent astrogliosis was also observed in adult animals. In contrast, an activation of microglial cells was transiently observed in the SNpc but only at the postnatal age when maximal neuronal death was observed (P30). Lastly, in the striatum, where there was a massive loss of DA nerve terminals, neither astrogliosis nor microglial activation was detected. Hence, the reaction of astrocytes and microglial cells to progressive and spontaneous DA neuronal death showed different temporal kinetics, suggesting a different role for these two cell types in the DA neurodegenerative process in the weaver mouse.


Subject(s)
Astrocytes/physiology , Cell Death/physiology , Dopamine/metabolism , Microglia/physiology , Neurons/physiology , Aging , Animals , Animals, Newborn , Cell Count , Glial Fibrillary Acidic Protein/metabolism , Homozygote , Immunohistochemistry , Macrophage-1 Antigen/metabolism , Mesencephalon/anatomy & histology , Mesencephalon/growth & development , Mesencephalon/metabolism , Mice , Mice, Neurologic Mutants , Tyrosine 3-Monooxygenase/metabolism
4.
Exp Neurol ; 176(1): 247-53, 2002 Jul.
Article in English | MEDLINE | ID: mdl-12093102

ABSTRACT

The effects of a chronic treatment with the anti-glutamate and sodium channel modulating neuroprotective agent riluzole on the degeneration of dopamine-containing neurons were studied in the brain of weaver mutant mice. In these animals, as in Parkinson's disease, dopaminergic neurons of the nigro-striatal pathway undergo spontaneous and progressive cell death. Homozygous weaver mice were orally treated twice a day with either 8 mg/kg riluzole or placebo for 2 months. Quantification of tyrosine-hydroxylase and dopamine-transporter axonal immunostaining in the striatum revealed that riluzole significantly increased the density of striatal dopaminergic nerve terminals. These results suggest that riluzole protects dopaminergic processes in the weaver mice and/or promotes their neuroplasticity.


Subject(s)
Corpus Striatum/drug effects , Membrane Glycoproteins , Nerve Tissue Proteins , Neuroprotective Agents/pharmacology , Parkinson Disease/drug therapy , Potassium Channels, Inwardly Rectifying , Riluzole/pharmacology , Substantia Nigra/drug effects , Animals , Corpus Striatum/metabolism , Corpus Striatum/pathology , Disease Models, Animal , Dopamine/metabolism , Dopamine Plasma Membrane Transport Proteins , Drug Administration Schedule , G Protein-Coupled Inwardly-Rectifying Potassium Channels , Homozygote , Membrane Transport Proteins/biosynthesis , Mice , Mice, Neurologic Mutants , Neurons/metabolism , Neurons/pathology , Parkinson Disease/genetics , Parkinson Disease/pathology , Potassium Channels/genetics , Presynaptic Terminals/drug effects , Presynaptic Terminals/pathology , Substantia Nigra/metabolism , Substantia Nigra/pathology , Time , Tyrosine 3-Monooxygenase/biosynthesis
SELECTION OF CITATIONS
SEARCH DETAIL
...